[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.249.135. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
January 1994

The Metabolic Effects of Platelet-Activating Factor Antagonism in Endotoxemic Man

Author Affiliations

From the Laboratory of Surgical Metabolism, Department of Surgery (Drs Thompson, Van Zee, Oldenburg, Rogy, Moldawer, and Lowry and Mss Coyle and Trousdale), and the Division of Urology (Dr Felsen), The New York Hospital—Cornell University Medical College, New York.

Arch Surg. 1994;129(1):72-79. doi:10.1001/archsurg.1994.01420250084011
Abstract

Objective:  To determine if the inflammatory phospholipid platelet-activating factor (PAF) participated in the symptomatologic, metabolic, and counterregulatory hormonal responses of human endotoxemia.

Design:  In a double-blind, placebo-controlled study, five subjects received 10 mg of the PAF antagonist Ro 24-4736 orally, while five control subjects received a placebo. Eighteen hours later, all subjects were administered 4 ng/kg of endotoxin (lipopolysaccharide) intravenously.

Setting:  The Clinical Research Center of The New York Hospital—Cornell Medical Center.

Participants:  Healthy male volunteers.

Main Outcome Measures:  Repeated measurements of vital signs, symptoms, cytokine and hormone levels, resting energy expenditure, platelet aggregation, and bleeding times were performed during a 24-hour period.

Results:  Subjects who were pretreated with the PAF antagonist experienced fewer symptoms, including rigors at 1 hour (P<.05) and myalgias at 1 through 4 hours (P<.05) after administration of lipopolysaccharide. This was in concert with a diminished peak cortisol level (668±107 vs 959± 159 nmol/L in controls; P<.05), epinephrine secretion (1057±165 vs 2029±431 nmol/L in controls; P<.05), and almost complete inhibition of PAF-induced platelet aggregation ex vivo.

Conclusions:  These findings in the face of unaltered circulating cytokines tumor necrosis factor α, interleukin 1β, and interleukin 6, as well as the tumor necrosis factor receptor-I s, suggest that PAF may influence some endotoxin-induced, counterregulatory hormonal responses and symptoms through cytokine-independent mechanisms. This study further supports the role of PAF antagonists as an adjunct to cytokine blockade in the treatment of gram-negative sepsis.(Arch Surg. 1994;129:72-79)

References
1.
Fong Y, Lowry SF.  Cytokines and the cellular response to injury and infection . In: Wilmore DW, Brennan MF, Harken AH, Holcroft JW, Meakins JL, eds. Care of the Surgical Patient . 1. New York, NY: Scientific American; 1990:1-17.
2.
Dobrowsky RT, Voyksner RD, Olson NC.  Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia . Am J Physiol . 1991; 260:H1455-H1465.
3.
Doebber TW, Wu MS, Robbins JC, Choy BM, Chang MN, Shen TY.  Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats: studies with PAF-receptor antagonist kadsurenone . Biochem Biophys Res Commun . 1985;127:799-808.Article
4.
Fink A, Geva D, Zung A, Konichezky S, Eliraz A, Bentwich Z.  Adult respiratory distress syndrome: roles of leukotriene C4 and platelet activating factor . Crit Care Med . 1990;18:905-910.Article
5.
Bussolino F, Porcellini MG, Varese L, Bosia A.  Intravascular release of platelet activating factor in children with sepsis . Thromb Res . 1987;48:619-620.Article
6.
Bessin P, Bonnet J, Apffel D, et al.  Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs . Eur J Pharmacol . 1983;86:403-413.Article
7.
Chang SW, Fernyak S, Voelkel NF.  Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury . Am J Physiol . 1990;258:H153-H158.
8.
Chang SW, Feddersen CO, Henson PM, Voelkel NF.  Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats . J Clin Invest . 1987;79:1498-1509.Article
9.
Lang CH, Dobrescu C, Hargrove DM, Bagby GJ, Spitzer JJ.  Attenuation of endotoxin-induced increase in glucose metabolism by platelet-activating factor antagonist . Circ Shock . 1987;23:179-188.
10.
Etienne A, Hecquet F, Soulard C, Spinnewyn B, Clostre F, Braquet P.  In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific PAF-acether antagonist: BN 52021 . Agents Actions . 1986;17:368-370.Article
11.
Fletcher JR, DiSimone AG, Earnest MA.  Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia . Ann Surg . 1990;211:312-316.
12.
Marano MA, Fong Y, Moldawer LL, et al.  Serum cachedin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality . Surg Gynecol Obstet . 1990;170:32-38.
13.
Tracey KJ, Beutler B, Lowry SF, et al.  Shock and tissue injury induced by recombinant human cachectin . Science . 1986;234:470-474.Article
14.
Tracey KJ, Fong Y, Hesse DG, et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia . Nature . 1987;330:662-664.Article
15.
Camussi G, Bussolino F, Salvido G, Baglioi C.  Tumor necrosis factor/cachectin stimulates macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor . J Exp Med . 1987; 166:1390-1404.Article
16.
Sun XM, Hsueh W.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor . J Clin Invest . 1988;81:1328-1331.Article
17.
Rabinovici R, Yue TL, Vernick J, Feuerstein G.  PAF and TNF alpha interactions in the pathophysiology of septic shock . Adv Exp Med Biol . 1991;314:193-203.
18.
Floch A, Bousseau A, Hetier E, Floch F, Bost PE, Cavero I.  RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release . J Lipid Mediat . 1989;1:349-360.
19.
Myers AK, Robey JW, Price RM.  Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice . Br J Pharmacol . 1990:99:499-502.Article
20.
Rabinovici R, Yue TL, Farhat M, et al.  Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist . J Pharmacol Exp Ther . 1990;255:256-263.
21.
Hochstein HD, Mills DF, Outschoorn HS, Rostogi SC.  The processing and collaborative assay of a reference endotoxin . J Biol Stand . 1983;11:251-260.Article
22.
Aitken RCB.  Measurement of feelings using a visual analogue scale . Proc R Soc Med . 1969;62:17-21.
23.
Hesse DG, Tracey KJ, Fong Y, et al.  Cytokine appearance in human endotoxemia and primate bacteremia . Surg Gynecol Obstet . 1988;166:147-153.
24.
Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo . Proc Natl Acad Sci U S A . 1992;89:4845-4849.Article
25.
Kenney JS, Masada MP, Eugui EM, Delustro BM, Mulkins MA, Allison AC.  Monoclonal antibodies to human recombinant interleukin 1 (IL-1) beta: quantitation of IL-1 beta and inhibition of bilogical activity . J Immunol . 1987;138:4236-4242.
26.
Aarden LA, Degroot ER, Schaap OL, Lansdorf P.  Production of hybridoma growth factor by human monocytes . Eur J Immunol . 1987;17:1411-1416.Article
27.
Aquilar-Parada A, Eisenstraut AM, Unger RH.  Effects of starvation on plasma pancreatic glucagon . Diabetes . 1969;18:717-723.
28.
Passon PG, Peuler JD.  A simplified radiometric assay for plasma norepinephrine and epinephrine . Ann Biochem . 1973;51:618-631.Article
29.
Calvano SE, Chiao J, Reaves LE, Antonacci AC, Shires GT.  Changes in free and total levels of plasma cortisol and thyroxin following thermal injury in man . J Burn Care Rehabil . 1984;5:143-151.Article
30.
Soeldner JS, Sloane D.  Critical variables in radioimmunoassay of serum insulin using the double antibody technique . Diabetes . 1965;14:771-779.
31.
Kuster LJ, Filep J, Frolich JC.  Mechanism of PAF-induced platelet aggregation in man . Thromb Res . 1986;43:425-433.Article
32.
Weir JBV.  New methods for calculating metabolic rate with special reference to protein metabolism . J Physiol Lond . 1949;109:1-9.
33.
Babson SR. Babson AL.  Development and evaluation of a disposable device for performing simultaneous duplicate bleeding time determinations . Am J Clin Pathol . 1978;70:406-408.
34.
Kuster LJ, Frolich JC.  Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man . Prostaglandins . 1986;32:415-423.Article
35.
Lopez DF, Nieto ML. Fernandez GS, Gijon MA, Sanchez CM.  Occupancy of platelet receptors for platelet-activating factor in patients with septicemia . J Clin Invest . 1989;83:1733-1740.Article
36.
Warren R, Starnes HF Jr, Gabrilove J, Oettgen H, Brennan MF.  The acute metabolic effects of tumor necrosis factor administration in humans . Arch Surg . 1987;122:1396-1400.Article
37.
Fong Y, Moldawer LL, Shires GT, Lowry SF.  The biological characteristics of cytokines and their implication in surgical injury . Surg Gynecol Obstet . 1990; 170:363-378.
38.
Van Zee KJ, Coyle SM, Calvano SE, et al. Influence of interleukin-1 receptor blockade in human endotoxemia. J Clin Invest. In press.
39.
Salzer WL, McCall CE.  Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury . J Clin Invest . 1990;85:1135-1143.Article
40.
Michie HR, Manogue KR, Spriggs DR, et al.  Detection of circulating tumor necrosis factor after endotoxin administration . N Engl J Med . 1988;318:1481-1486.Article
41.
Terashita Z, Imura Y, Nishikawa K, Sumida S.  Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol . 1985;109:257-261.Article
42.
Sessler CN, Glauser FL, Davis D, Fowler AA III.  Effects of platelet-activating factor antagonist SRI 63-441 on endotoxemia in sheep . J Appl Physiol . 1988; 65:2624-2631.
43.
Thompson WA, Van Zee KJ, Kumar A, et al.  Platelet-activating factor antagonist (Ro24-4736) attenuates the metabolic response to gram-negative sepsis in primates . Surg Forum . 1992;48:84-87.
44.
Lang CH, Dobrescu C, Hargrove DM, Bagby GJ, Spitzer JJ.  Platelet-activating factor—induced increases in glucose kinetics . Am J Physiol . 1988;254:E193-E200.
45.
Maier RV, Hahnel GB, Fletcher JR.  Platelet-activating factor augments tumor necrosis factor and procoagulant activity . J Surg Res . 1992;52:258-264.Article
×